

# **Clinical and virological features of chronic hepatitis B in the French National Surveillance Program, 2008-2012**

Stéphane Chevaliez, Françoise Roudot-Thoraval, Cécile Brouard, Emmanuel  
Gordien, Fabien Zoulim, Ségolène Brichler, Véronique Brodard, Corinne Pioche,  
Jean-Michel Pawlotsky, Vincent Leroy, and the Hepatology Reference Centers and  
Laboratories Network for Chronic Hepatitis B Surveillance

## Table of contents

Table S1.....	2
Table S2.....	3
Table S3.....	4
List of Hepatology Reference Centers and Laboratories Network for Chronic Hepatitis B Surveillance.....	5

**Table S1:** Eligibility criteria for antiviral treatment according to EASL 2017 guidelines

<b>HBeAg status</b>	<b>HBV DNA (IU/mL)</b>	<b>ALT</b>	<b>Necro-inflammation or fibrosis</b>	<b>Other</b>
Negative or positive	>2000	>1xULN	≥A2 or ≥F2	
Negative or positive	>20,000	>2xULN		
Negative or positive	detectable		≥F4	
Positive	>20,000			Age >30 years

**Table S2:** Baseline characteristics of patients with (n=33) and without (n=501) delta infection

	HDV+ve	HDV-ve	P value*
Age, years (median [IQR])	43 [32-52.5]	37 [29-50]	$p < 0.001$
Sex, male [n (%)]	26 (78.8)	299 (59.7)	$p < 0.001$
Detectable HBV DNA [n (%)]	20 (60.6)	440 (87.9)	$p < 0.001$
HBV DNA level (Log IU/mL), (median [IQR])	2.7 [1.8-4.0]	3.3 [2.5-4.5]	$p = 0.004$
HBsAg level (Log IU/mL), (median [IQR])	3.3 [1.2-3.9]	3.6 [3.0-4.1]	$p = 0.034$
HBV genotype [n (%)]			
A	3 (16.7)	100 (20.0)	
B/C	1 (5.6)	47 (9.4)	
D	9 (50.0)	136 (27.2)	$p = 0.021$
E	5 (27.8)	107 (21.4)	
Significant fibrosis ( $\geq$ F2) [n (%)]	13 (54.2)	44 (8.8)	$p = 0.003$
ALT >40 U/L [n (%)]	17 (56.7)	173 (34.5)	$p < 0.001$

\*Based on Kruskal-Wallis test was used when categorical variables had more than 2 classes and the correction of Bonferroni was used for multiple comparisons

**Table S3:** Baseline characteristics of patients with (n=360) and without (n=99) fibrosis stage assessment

	With	Without	P value*
Age, years (median [IQR])	36 [28-49]	40 [29-53]	$p = 0.064$
Sex, male [n (%)]	224 (62.2)	51 (51.5)	$p = 0.127$
BMI (kg/m <sup>2</sup> ), (median [IQR])	24 [22-27]	26 [22-30]	$p = 0.095$
History of alcohol abuse [n (%)]	14 (4.3)	7 (8.5)	$p = 0.159$
History of intravenous drug use [n (%)]	1 (0.3)	2 (3.0)	$p = 0.081$
Country of birth [n (%)]			
France	81 (81.8)	18 (18.2)	
Europe, excluding France	35 (72.9)	13 (27.1)	
North Africa	30 (88.2)	4 (11.8)	
Middle-East	11 (52.4)	10 (47.6)	$p = 0.002$
Asia	43 (87.8)	6 (12.2)	
West Indies	13 (48.1)	14 (51.9)	
Sub-Saharan Africa	144 (82.8)	30 (17.2)	
HBV DNA level (Log IU/mL), (median [IQR])	3.4 [2.5-4.6]	3.2 [2.3-4.0]	$p = 0.038$
HBsAg level (Log IU/mL), (median [IQR])	3.7 [3.0-4.1]	3.7 [3.0-4.0]	$p = 0.492$
ALT level (U/L) (median [IQR])	32 [21-50]	33 [24-46]	$p = 0.674$
ALT >40 U/L [n (%)]	113 (32.3)	20 (22.7)	$p = 0.092$

\*Based on Kruskal-Wallis test was used when categorical variables had more than 2 classes and the correction of Bonferroni was used for multiple comparisons

List of Hepatology Reference Centers and Laboratories Network for Chronic Hepatitis B Surveillance:

Prof. M Doffoël, Dr. A Edouard, Dr. E Saillard, Prof. P Couzigou, Prof. V de Ledinghen, Prof. P Hillon, Prof. D Guyader, Prof. EH Metman, Prof. Y Bacq, Dr. X Causse, Prof. G Thieffin, Prof. V di Martino, Prof. JP Miguet, Prof. T Dao, Prof. E Lerebourg, Prof. D Valla, Prof. P Marcellin, Prof. R Poupon, Prof. A Mallat, Prof. S Pol, Prof. D Larrey, Dr. A-J Remy, Prof. B Pillegrand, Prof. D Sautereau, Prof. JJ Raabe, Prof. J-P Bronowicki, Prof. JP Vinel, Prof. Cortot, Prof. P Calès, Prof. JL Dupas, Prof. M Moricheau-Beauchant, Prof. Botta-Fridlund, Prof. A Tran, Prof. F Zoulim, Prof. J-P Zarski, Prof. V Leroy, Prof. M Beaugrand, Prof. D Roulot, Prof. D Samuel.

Dr. E Schvoerer, Dr. F Najioullah, Dr. P Trimoulet, Dr. J-B Bour, Dr. S Minjolle, Prof. C Gaudy-Graffin, Dr. M Macé, Dr. V Brodard, Dr. D Bettinger, Dr. J Petitjean, Prof. J-C Plantier, Dr. M Martinot, Dr. J Gozlan, Dr. J-F Méritet, Dr. J Ducos, Dr. S Gaba, Prof. S Alain, Dr. Delamare, Dr. V Venard, Dr. F Abravanel, Dr. L Bocket, Prof. F Lunel, Prof. G Duverlie, Dr. A Bourgoin, Dr. P Colson, Dr. L Ollier, Dr. P Chevalier-Queyron, Dr. S Larrat, Dr. S Brichler, Dr. E Gordien, Prof. A-M Roque-Afonso, Prof. S Chevaliez.